IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models

IgA3.0 ch14.18 contains a more favorable glycosylation pattern, corresponding to an increased antibody half-life in mice . The molecule has increased stability and increased protein stability enabling effortless production and purification . It penetrates neuroblastoma tumors in vitro and halts tumor outgrowth in both 9464D-GD2 and IMR32 long-term tumor models .

Published
Categorized as Oncology

Leave a Reply